retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide vs Ozempic: Clinical Trial

How might next-generation GLP-1 therapies be combined with other treatments to maximize benefits across metabolic and cardiovascular disease

Additionally, longitudinal studies are needed to determine whether prolonged Retatrutide treatment leads to adaptive metabolic responses, such as thermogenic compensation or receptor desensitization

Klaritys licensed providers can evaluate whether GLP-1 medications may be right for you fully online, same-day appointments available with 2,000+ providers, and many insurance plans may cover your visit

Ozempic is made to help you control your blood sugar

This means Canadian patients likely will not have access to prescription Retatrutide through standard healthcare channels until 2027 or 2028

The research investigates how it can regulate appetite, blood pressure, and body weight via multiple hormonal mechanisms